Back to Search Start Over

Protein typing of major outer membrane lipoproteins from Chinese pathogenic Leptospira spp. and characterization of their immunogenicity

Authors :
Luo, Dongjiao
Xue, Feng
Ojcius, David M.
Zhao, Jinfang
Mao, Yafei
Li, Liwei
Lin, Xuai
Yan, Jie
Source :
Vaccine. Dec2009, Vol. 28 Issue 1, p243-255. 13p.
Publication Year :
2009

Abstract

Abstract: Leptospirosis, caused by different Leptospira species, is one of the most widespread zoonotic infections worldwide. Here we expressed three major leptospiral lipoproteins and examined their immunogenicity. All the pathogenic Leptospira strains tested possess the lipL21, lipL32 and lipL41 genes, but the latter two can be further divided into different gene types (lipL32-1, lipL32-2, lipL41-1, lipL41-2). Microscopic agglutination test revealed that rLipLs antisera had extensive cross-immunoagglutination among the 178 leptospiral strains in which rLipL32-1 contributed the highest agglutination titer. The rLipLs-based ELISAs established in this study demonstrated that in the sera of 385 leptospirosis patients infected with different serovars of Leptospira interrogans, rLipL32-1 had the highest positive rates for IgG and IgM (89.4–98.7%), followed by the IgG/IgM positive rates of rLipL21 (87.0–96.1%) and rLipL32-2 (86.5–96.9%), while the two rLipL41s presented the lowest IgG/IgM positive rates (69.9–83.9%). The immunoprotective levels in guinea pigs of rLipL32-1 (58.3% and 66.7%) were the highest, compared to those of the other rLipLs (25.0–58.3%). Multiple different rLipLs would increase immunoprotective levels (from 58.3% and 66.7% to 83.3% and 91.7%). The data suggest that all the rLipLs are the genus-specific superficial antigens of pathogenic Leptospira species and should be considered in designing universal vaccines against leptospirosis. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
0264410X
Volume :
28
Issue :
1
Database :
Academic Search Index
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
45556537
Full Text :
https://doi.org/10.1016/j.vaccine.2009.09.089